Cargando…

Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma

BACKGROUND: Liver fibrosis is a middle stage in the course of chronic Hepatitis B virus (HBV) infection, which will develop into cirrhosis and eventually hepatocellular carcinoma (HCC) if not treated at the early stage. Considering the limitations and patients' reluctance to undergo liver biops...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Ye, Liu, Jie, Lin, Chengzhao, Wang, Haijian, Jiang, Ying, Wang, Jiyao, Yang, Pengyuan, He, Fuchu
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959091/
https://www.ncbi.nlm.nih.gov/pubmed/20939925
http://dx.doi.org/10.1186/1471-230X-10-115
_version_ 1782188438199468032
author Lu, Ye
Liu, Jie
Lin, Chengzhao
Wang, Haijian
Jiang, Ying
Wang, Jiyao
Yang, Pengyuan
He, Fuchu
author_facet Lu, Ye
Liu, Jie
Lin, Chengzhao
Wang, Haijian
Jiang, Ying
Wang, Jiyao
Yang, Pengyuan
He, Fuchu
author_sort Lu, Ye
collection PubMed
description BACKGROUND: Liver fibrosis is a middle stage in the course of chronic Hepatitis B virus (HBV) infection, which will develop into cirrhosis and eventually hepatocellular carcinoma (HCC) if not treated at the early stage. Considering the limitations and patients' reluctance to undergo liver biopsy, a reliable, noninvasive diagnostic system to predict and assess treatment and prognosis of liver fibrosis is needed. The aim of this study was to identify biomarkers for early diagnosis of HBV related liver fibrosis. METHOD: Plasma samples from 7 healthy volunteers and 27 HBV infected patients with different stages of fibrosis were selected for 2-DIGE proteomic screening. One-way ANOVA analysis was used to assess differences in protein expression among all groups. The alteration was further confirmed by western blotting. Plasma levels of 25 serological variables in 42 healthy volunteers and 68 patients were measured to establish a decision tree for the detection of various stages fibrosis. RESULT: The up-regulated proteins along with fibrosis progress included fibrinogen, collagen, macroglobulin, hemopexin, antitrypsin, prealbumin and thioredoxin peroxidase. The down-regulated proteins included haptoglobin, serotransferrin, CD5 antigen like protein, clusterin, apolipoprotein and leucine-rich alpha-2-glycoprotein. For the discrimination of milder stage fibrosis, the area under curve for Prx II was the highest. Four variables (PT, Pre, HA and Prx II) were selected from the 25 variables to construct the decision tree. In a training group, the correct prediction percentage for normal control, milder fibrosis, significant fibrosis and early cirrhosis was 100%, 88.9%, 95.2% and 100%, respectively, with an overall correct percent of 95.9%. CONCLUSION: This study showed that 2-D DIGE-based proteomic analysis of the plasma was helpful in screening for new plasma biomarkers for liver disease. The significant up-expression of Prx II could be used in the early diagnosis of HBV related liver fibrosis.
format Text
id pubmed-2959091
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29590912010-10-22 Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma Lu, Ye Liu, Jie Lin, Chengzhao Wang, Haijian Jiang, Ying Wang, Jiyao Yang, Pengyuan He, Fuchu BMC Gastroenterol Research Article BACKGROUND: Liver fibrosis is a middle stage in the course of chronic Hepatitis B virus (HBV) infection, which will develop into cirrhosis and eventually hepatocellular carcinoma (HCC) if not treated at the early stage. Considering the limitations and patients' reluctance to undergo liver biopsy, a reliable, noninvasive diagnostic system to predict and assess treatment and prognosis of liver fibrosis is needed. The aim of this study was to identify biomarkers for early diagnosis of HBV related liver fibrosis. METHOD: Plasma samples from 7 healthy volunteers and 27 HBV infected patients with different stages of fibrosis were selected for 2-DIGE proteomic screening. One-way ANOVA analysis was used to assess differences in protein expression among all groups. The alteration was further confirmed by western blotting. Plasma levels of 25 serological variables in 42 healthy volunteers and 68 patients were measured to establish a decision tree for the detection of various stages fibrosis. RESULT: The up-regulated proteins along with fibrosis progress included fibrinogen, collagen, macroglobulin, hemopexin, antitrypsin, prealbumin and thioredoxin peroxidase. The down-regulated proteins included haptoglobin, serotransferrin, CD5 antigen like protein, clusterin, apolipoprotein and leucine-rich alpha-2-glycoprotein. For the discrimination of milder stage fibrosis, the area under curve for Prx II was the highest. Four variables (PT, Pre, HA and Prx II) were selected from the 25 variables to construct the decision tree. In a training group, the correct prediction percentage for normal control, milder fibrosis, significant fibrosis and early cirrhosis was 100%, 88.9%, 95.2% and 100%, respectively, with an overall correct percent of 95.9%. CONCLUSION: This study showed that 2-D DIGE-based proteomic analysis of the plasma was helpful in screening for new plasma biomarkers for liver disease. The significant up-expression of Prx II could be used in the early diagnosis of HBV related liver fibrosis. BioMed Central 2010-10-13 /pmc/articles/PMC2959091/ /pubmed/20939925 http://dx.doi.org/10.1186/1471-230X-10-115 Text en Copyright ©2010 Lu et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lu, Ye
Liu, Jie
Lin, Chengzhao
Wang, Haijian
Jiang, Ying
Wang, Jiyao
Yang, Pengyuan
He, Fuchu
Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma
title Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma
title_full Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma
title_fullStr Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma
title_full_unstemmed Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma
title_short Peroxiredoxin 2: a potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma
title_sort peroxiredoxin 2: a potential biomarker for early diagnosis of hepatitis b virus related liver fibrosis identified by proteomic analysis of the plasma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2959091/
https://www.ncbi.nlm.nih.gov/pubmed/20939925
http://dx.doi.org/10.1186/1471-230X-10-115
work_keys_str_mv AT luye peroxiredoxin2apotentialbiomarkerforearlydiagnosisofhepatitisbvirusrelatedliverfibrosisidentifiedbyproteomicanalysisoftheplasma
AT liujie peroxiredoxin2apotentialbiomarkerforearlydiagnosisofhepatitisbvirusrelatedliverfibrosisidentifiedbyproteomicanalysisoftheplasma
AT linchengzhao peroxiredoxin2apotentialbiomarkerforearlydiagnosisofhepatitisbvirusrelatedliverfibrosisidentifiedbyproteomicanalysisoftheplasma
AT wanghaijian peroxiredoxin2apotentialbiomarkerforearlydiagnosisofhepatitisbvirusrelatedliverfibrosisidentifiedbyproteomicanalysisoftheplasma
AT jiangying peroxiredoxin2apotentialbiomarkerforearlydiagnosisofhepatitisbvirusrelatedliverfibrosisidentifiedbyproteomicanalysisoftheplasma
AT wangjiyao peroxiredoxin2apotentialbiomarkerforearlydiagnosisofhepatitisbvirusrelatedliverfibrosisidentifiedbyproteomicanalysisoftheplasma
AT yangpengyuan peroxiredoxin2apotentialbiomarkerforearlydiagnosisofhepatitisbvirusrelatedliverfibrosisidentifiedbyproteomicanalysisoftheplasma
AT hefuchu peroxiredoxin2apotentialbiomarkerforearlydiagnosisofhepatitisbvirusrelatedliverfibrosisidentifiedbyproteomicanalysisoftheplasma